174 results on '"Nishioka, Naoya"'
Search Results
2. Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma
3. Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)
4. Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status
5. AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells
6. Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis
7. Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
8. Initial AXL and MCL‐1 inhibition contributes to abolishing lazertinib tolerance in EGFR‐mutant lung cancer cells.
9. Clinical significance of chronic pulmonary aspergillosis in lung cancer patients undergoing anticancer drug therapy.
10. The Significance of Longitudinal Psoas Muscle Loss in Predicting the Maintenance Efficacy of Durvalumab Treatment Following Concurrent Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer: A Retrospective Study.
11. Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer
12. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma
13. Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy
14. Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer
15. Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
16. Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non‐small cell lung cancer.
17. A Case of Bronchobiliary Fistula Successfully Treated for Bronchial Occlusion Using Endobronchial Watanabe Spigot and Embolization Coils
18. Correction to: Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non‑small cell lung cancer
19. A protocol of a single arm, prospective, open-label, multicenter, phase II study of ramucirumab and erlotinib in treatment-naïve non-small cell lung cancer patients with EGFR mutation and brain metastases (SPIRAL-BRAIN study)
20. Figure S1-S10 from ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non–Small Cell Lung Cancer
21. Incidence and Treatment Outcome of Radiation Pneumonitis in Patients With Limited-stage Small Cell Lung Cancer Treated With Concurrent Accelerated Hyperfractionated Radiation Therapy and Chemotherapy
22. Real-world data concerning the efficacy of molnupiravir in patients vaccinated against COVID-19 during the Omicron surge in Japan
23. The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations
24. High levels of AXL expression in untreatedEGFR‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib
25. Clinical impact of tumour burden on the efficacy of PD ‐1/ PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer
26. MO44-5 The clinical outcome of patients with oligometastatic non-small cell lung cancer treated with first-line immunotherapy
27. Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in advanced non‐small cell lung cancer
28. Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer
29. Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR ‐T790M mutation in non‐small cell lung cancer cells
30. High levels of AXL expression in untreated EGFR‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib.
31. Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer.
32. Correction to: Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non‑small cell lung cancer
33. Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis
34. Long-term outcomes in extensive disease small cell lung cancer patients treated without immune checkpoint inhibitors
35. Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
36. Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation
37. Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer
38. Long-Term Survival Data of Patients With Limited-Disease Small-Cell Lung Cancer
39. Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study
40. Association Between Oligo-Residual Disease and Patterns of Failure During EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer: A Retrospective Study
41. Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis
42. MO21-1 Prognostic value of pneumonitis after durvalumab in locally-advanced non-small cell lung cancer
43. Impact of Cancer Cachexia on Treatment With PD-1/PD-L1 Inhibitors Plus Chemotherapy in Advanced Non-small-Cell Lung Cancer
44. Additional file 1 of Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
45. Impact of prior ALK-tyrosine kinase inhibitor on pemetrexed-based chemotherapy in patients with advanced ALK positive non-small cell lung cancer.
46. Long-Term Survival in Extensive Disease Small Cell Lung Cancer Patients Treated Without Immune Checkpoint Inhibitors
47. Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression
48. Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non‐small cell lung cancer
49. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma
50. The Quality of Life of Patients with Suspected Lung Cancer before and after Bronchoscopy and the Effect of Mirtazapine on the Depressive Status
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.